Saturday 17 October 2026
Export BMRN’s income statement to Excel — free account
BioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
54.68
1.37
−2.44%
Follow BMRN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
150.58 | 40.35 | 32.65 | 19.91 |
+8 more quarters Free account |
P/S ratio |
3.25 | 3.35 | 3.54 | 3.36 | |
P/FCF ratio |
15.27 | 14.32 | 15.90 | 12.59 | |
P/Operating CF |
65.84 | 49.28 | 114.39 | 28.21 | |
P/B ratio |
1.75 | 1.75 | 1.87 | 1.72 | |
Price to Tangible BV |
14.07 | 1.87 | 2.01 | 1.85 | |
EV/Sales |
4.22 | 3.26 | 3.39 | 3.24 | |
EV/EBITDA |
48.35 | 27.46 | 22.57 | 14.45 | |
EV/Operating CF |
16.78 | 12.10 | 13.20 | 10.96 | |
EV/FCF |
19.84 | 13.93 | 15.24 | 12.13 | |
Quick Ratio |
1.16 | 3.94 | 3.25 | 2.84 | |
Current Ratio |
2.39 | 5.81 | 5.21 | 4.83 | |
Net Debt/EBITDA |
15.85 | (5.44) | 38.11 | 27.62 | |
Debt/Assets |
35.71% | 16.65% | 7.86% | 7.84% | |
Debt/Equity |
0.66 | 0.23 | 0.10 | 0.10 | |
Asset Turnover |
0.36 | 0.41 | 0.44 | 0.43 | |
Operating CF/Net income |
3.76 | 2.09 | (2.14) | (11.99) | |
Capex/Depreciation |
(0.35) | (1.31) | (2.23) | (2.28) | |
Interest Coverage |
1.75 | 8.67 | (16.06) | (18.10) | |
Research and Development Expense of Revenue |
20.91% | 23.34% | 22.00% | 52.76% | |
Selling, General and Administrative Expense of Revenue |
39.97% | 33.71% | 51.02% | 34.58% | |
Intangible Assets out of Total Assets |
0.47 | 0.05 | 0.05 | 0.06 | |
Share Based Compensation of Revenue |
7.65% | 5.67% | 5.36% | 6.35% | |
Graham Net Nets |
(0.13) | 0.20 | 0.21 | 0.22 | |
Graham Number |
16.72 | 31.88 | 36.05 | 43.93 | |
Earnings Yield |
0.66% | 2.48% | 3.06% | 5.02% | |
Free Cash Flow Yield |
6.55% | 6.98% | 6.29% | 7.94% | |
Revenue per Share |
5.12 | 3.98 | 4.56 | 4.04 | |
Operating CF per Share |
0.87 | 1.15 | 0.52 | 1.92 | |
Capex per Share |
(0.18) | (0.11) | (0.22) | (0.18) | |
Free Cash Flow per Share |
0.69 | 1.04 | 0.29 | 1.74 | |
Cash per Share |
4.52 | 11.55 | 8.14 | 7.70 | |
Shareholders Equity per Share |
32.68 | 32.27 | 31.74 | 31.54 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
32.68 | 32.27 | 31.74 | 31.54 | |
Free Cash Flow |
133.86 | 199.73 | 56.55 | 334.94 | |
Working Capital |
2,307.63 | 3,811.92 | 3,194.46 | 3,056.11 | |
Capital Expenditures |
(34.25) | (20.92) | (43.09) | (33.75) | |
Net Current Asset Value |
(1,430.13) | 2,226.16 | 2,446.47 | 2,296.39 | |
EV/EBIT |
96.34 | 33.55 | 26.69 | 16.27 | |
Capex to Sales |
0.03 | 0.03 | 0.05 | 0.04 | |
Price to Operating Income |
74.15 | 34.50 | 27.84 | 16.90 | |
| Other line items | |||||
Average Receivables |
958.45 | 821.55 | 784.37 | 783.91 | |
Average Payables |
845.02 | 710.68 | 683.01 | 757.05 | |
Average Inventory |
1,561.35 | 1,274.03 | 1,265.77 | 1,280.76 | |
Average Assets |
9,589.89 | 7,869.01 | 7,291.48 | 7,233.03 | |
Average Common Equity |
6,174.40 | 6,002.78 | 5,872.49 | 5,735.05 |
Columns are period end dates